A Phase I First|in|Human Study of ABBV|011

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

ABBV-011 1.0 mg/kg every 3 weeks monotherapy was well tolerated and demonstrated encouraging antitumor activity in heavily pretreated patients with ...

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

Abstract. Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody ...

First-in-human study of ABBV-011, a seizure-related homolog ...

First-in-human study of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–targeting antibody-drug conjugate, in patients with small cell lung ...

A Phase 1 Study of ABBV-011 as a Single-Agent and in ...

... first dose of study drug. Additional Inclusion Criteria for Study Part B and Part C: - SCLC tumor tissue that tests positive for seizure-related homolog 6 ...

ABBV-011 Demonstrates Preliminary Efficacy, Safety in R/R SCLC

Investigators report no deaths related to treatment with ABBV-011 among patients with small cell lung cancer in a first-in-human phase 1 trial.

ADC With Novel SEZ6 Target Well-Tolerated With Preliminary ...

ABBV-011 was well-tolerated and demonstrated antitumor activity in a first-in-human, phase 1 trial of patients with relapsed/refractory SCLC ...

A Phase 1 Study of ABBV-011 as a Single ... - Scholars@Duke grant

A Phase 1 Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed or Refractory Small Cell Lung Cancer.

ABBV-011 Achieves Antitumor Activity and Tolerable Safety in Small ...

Results from a first-in-human phase 1 trial (NCT03639194) shows that ABBV-011, a SEZ6-targeted antibody-drug conjugate (ADC), given every 3 ...

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small ...

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug ...

This phase 1 study evaluates safety and clinical activity of ABBV-319 monotherapy in patients with relapsed or refractory (R/R) B-cell malignancies.

Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics ...

ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups ...

770 Safety, efficacy, and pharmacokinetic results from a phase I first ...

Herein, we report preliminary safety, efficacy, and pharmacokinetic (PK) results from a first-in-human, phase 1 study (NCT03821935) assessing ABBV-151 ± ...

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

Figures for A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, ...

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation ...

ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study.

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO ...

Dose escalation results from a first-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors.

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

Download Citation | A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, ...

A Phase 1 First-in-human Study to Investigate the Safety, Tolerability ...

By activating eIF2B, ABBV-CLS-7262 may attenuate the Integrated Stress Response and restore protein translation. Design/Methods: This multi-part Phase 1 study ...

A Study of ABBV-011 Alone and in Combination With Budigalimab ...

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer.

NCT03639194 - ClinicalTrials.gov

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell ...